Abstract:Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME remains largely unexplored. Here we show that the secreted frizzled-related protein 2 (SFRP2), a Wnt pathway modulator, is produced by human primary fibroblasts after genotoxic treatments. SFRP2 induction is remarkable in tumor stroma, with transcription mainly modulated by the nuclear factor-κB (NF-κB) complex, a property shared by several effectors of the DNA damage secretory program. Instead of directly altering canonical Wnt signaling, SFRP2 augments β-catenin activities initiated by WNT16B, another soluble factor from DNA-damaged stroma. WNT16B recognizes cancer cell surface receptors including frizzled (FZD) 3/4/6, a process enhanced by SFRP2, coordinated by the co-receptor LRP6 but subject to abrogation by DKK1. Importantly, we found WNT16B plays a central role in promoting advanced malignancies particularly acquired resistance by counteracting cell death, an effect that can be minimized by a neutralizing antibody co-administered with classical chemotherapy. Furthermore, DNA damage-triggered expression of WNT16B is systemic, imaged by significant induction among diverse solid organs and circulation in peripheral blood, thereby holding promise as not only a TME-derived anticancer target but also a novel biomarker for clinical evaluation of treatment efficacy. Overall, our study substantiates the biological complexity and pathological implication of a therapy-activated TME, and provides the proof of principle of co-targeting tumor and the TME to prevent acquired resistance, with the aim of improving intervention outcome in an era of precision medicine.

Role of secreted frizzled-related proteins in cancer

Progress in understanding the relationship between SFRP gene methylation and gastrointestinal tumors

SFRP4 Was Overexpressed in Colorectal Carcinoma

Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease

Involvement of genetic instability in the downregulation of sFRP1 in Chinese patients with hepatocellular carcinoma.

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers

Secreted Frizzled Related Proteins in Cardiovascular and Metabolic Diseases

SFRP1 mediates cancer-associated fibroblasts to suppress cancer cell proliferation and migration in head and neck squamous cell carcinoma

Secreted frizzled-related protein 4 and its implications in cancer and apoptosis

High levels of secreted frizzled-related protein 1 correlate with poor prognosis and promote tumourigenesis in gastric cancer.

Secreted Frizzled-Related Protein 2 is Epigenetically Silenced and Functions As A Tumor Suppressor in Oral Squamous Cell Carcinoma

Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma

Effects of Secreted Frizzled-Related Protein 1 on Proliferation, Migration, Invasion, and Apoptosis of Colorectal Cancer Cells

Sfrp1 Inhibits Epithelial-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cell Line

Deregulation of Secreted Frizzled-Related Proteins is Associated with Aberrant Β-Catenin Activation in the Carcinogenesis of Oral Submucous Fibrosis.

Demethylation of the SFRP4 Promoter Drives Gastric Cancer Progression Via the Wnt Pathway.

SFRP2 Augments WNT16B Signaling to Promote Therapeutic Resistance in the Damaged Tumor Microenvironment.

Transcriptional expression, prognostic value and immune infiltration of SFRP family in colorectal cancer: a study based on comprehensive bioinformatics and in vitro analyses

Krüppel-like factors in tumors: Key regulators and therapeutic avenues

Frizzled7 as an emerging target for cancer therapy

The emerging understanding of Frizzled receptors